Skip to main content

Advertisement

SpringerLink
Log in

Survivin in Solid Tumors: Rationale for Development of Inhibitors

  • Evolving Therapies (RM Bukowski, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Survivin is a 16.5 kDa protein that functions to inhibit apoptosis, promote proliferation, and enhance invasion. Absent in most adult tissues, survivin is selectively upregulated in many human tumors, where its overexpression correlates with poor outcome and treatment resistance. Consequently, survivin is a promising target for cancer therapy. Preclinical data demonstrate that survivin inhibition reduces cell proliferation, increases apoptosis, and sensitises cells to cytotoxic agents and radiotherapy. The pharmacological survivin inhibitors LY2181308 and YM155 have demonstrated acceptable toxicity and evidence of therapeutic efficacy as single agents in early-phase clinical trials. Current efforts seek to define the optimum use of survivin inhibitors in combination with cytotoxic therapies, where it is hoped that preclinical evidence of treatment synergy will translate into improved therapeutic efficacy. Results from these ongoing studies are keenly awaited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. Altieri DC. New wirings in the survivin networks. Oncogene. 2008;27:6276–84.

    Article  PubMed  CAS  Google Scholar 

  2. • Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61-70. Excellent review which presents an elegant summary of current knowledge of survivin biology.

  3. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer. 2005;4:11.

    Article  PubMed  Google Scholar 

  4. Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun. 2004;314:902–7.

    Article  PubMed  CAS  Google Scholar 

  5. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59:6097–102.

    PubMed  CAS  Google Scholar 

  6. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DCC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 1998;152:43–9.

    PubMed  CAS  Google Scholar 

  7. Uren AG, Wong L, Pakusch M, et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000;10:1319–28.

    Article  PubMed  CAS  Google Scholar 

  8. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–21.

    Article  PubMed  CAS  Google Scholar 

  9. Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ, Boman BM. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 2001;61:8664–7.

    PubMed  CAS  Google Scholar 

  10. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood. 2001;98:2091–100.

    Article  PubMed  CAS  Google Scholar 

  11. Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32:119–25.

    Article  PubMed  CAS  Google Scholar 

  12. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5:1087–98.

    Article  PubMed  CAS  Google Scholar 

  13. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006;18:609–15.

    Article  PubMed  CAS  Google Scholar 

  14. Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol. 2006;18:616–22.

    Article  PubMed  CAS  Google Scholar 

  15. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003;101:1535–42.

    Article  PubMed  CAS  Google Scholar 

  16. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene. 2007;26:2678–84.

    Article  PubMed  CAS  Google Scholar 

  17. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res. 2008;14:1581–9.

    Article  PubMed  CAS  Google Scholar 

  18. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000;113(Pt 23):4363–71.

    PubMed  CAS  Google Scholar 

  19. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science. 2005;310:1499–504.

    Article  PubMed  CAS  Google Scholar 

  20. O’Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell. 2002;2:43–54.

    Article  PubMed  Google Scholar 

  21. Wheatley SP, Barrett RM, Andrews PD, et al. Phosphorylation by aurora-B negatively regulates survivin function during mitosis. Cell Cycle. 2007;6:1220–30.

    Article  PubMed  CAS  Google Scholar 

  22. Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell. 2007;27:17–28.

    Article  PubMed  CAS  Google Scholar 

  23. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol. 2000;7:602–8.

    Article  PubMed  CAS  Google Scholar 

  24. Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O, Margolis RL. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell. 2000;6:183–9.

    PubMed  CAS  Google Scholar 

  25. Jeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA, Conti E. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell. 2007;131:271–85.

    Article  PubMed  CAS  Google Scholar 

  26. Kang BH, Altieri DC. Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J Biol Chem. 2006;281:24721–7.

    Article  PubMed  CAS  Google Scholar 

  27. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A. 2003;100:13791–6.

    Article  PubMed  CAS  Google Scholar 

  28. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54.

    Article  PubMed  CAS  Google Scholar 

  29. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5:897–907.

    Article  PubMed  CAS  Google Scholar 

  30. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–9.

    Article  PubMed  CAS  Google Scholar 

  31. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315–20.

    PubMed  CAS  Google Scholar 

  32. Banks DP, Plescia J, Altieri DC, et al. Survivin does not inhibit caspase-3 activity. Blood. 2000;96:4002–3.

    PubMed  CAS  Google Scholar 

  33. Li C, Wu Z, Liu M, Pazgier M, Lu W. Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci. 2008;17:1624–9.

    Article  PubMed  CAS  Google Scholar 

  34. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006;7:988–94.

    Article  PubMed  CAS  Google Scholar 

  35. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003;22:2729–40.

    Article  PubMed  CAS  Google Scholar 

  36. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580–4.

    Article  PubMed  CAS  Google Scholar 

  37. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci U S A. 2004;101:15100–5.

    Article  PubMed  CAS  Google Scholar 

  38. Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, Stukenberg PTC. Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell. 2002;13:3064–77.

    Article  PubMed  CAS  Google Scholar 

  39. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol. 2001;11:886–90.

    Article  PubMed  CAS  Google Scholar 

  40. Sampath SC, Ohi R, Leismann O, Salic A, Pozniakovski A, Funabiki H. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell. 2004;118:187–202.

    Article  PubMed  CAS  Google Scholar 

  41. Sandall S, Severin F, McLeod IX, et al. A Bir1-Sli15 complex connects centromeres to microtubules and is required to sense kinetochore tension. Cell. 2006;127:1179–91.

    Article  PubMed  CAS  Google Scholar 

  42. Rosa J, Canovas P, Islam A, Altieri DC, Doxsey SJ. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell. 2006;17:1483–93.

    Article  PubMed  CAS  Google Scholar 

  43. Ghosh JC, Dohi T, Raskett CM, Kowalik TF, Altieri DC. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res. 2006;66:11576–9.

    Article  PubMed  CAS  Google Scholar 

  44. O’Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol. 2000;156:393–8.

    Article  PubMed  Google Scholar 

  45. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A. 2002;99:4349–54.

    Article  PubMed  CAS  Google Scholar 

  46. Zwerts F, Lupu F, De Vriese A, et al. Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood. 2007;109:4742–52.

    Article  PubMed  CAS  Google Scholar 

  47. • Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. IAP regulation of metastasis. Cancer Cell. 2010;17:53-64. Exciting paper demonstrating new role for survivin in promotion of tumor invasion and metastasis.

  48. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999;23:387–8.

    Article  PubMed  CAS  Google Scholar 

  49. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882–3.

    Article  PubMed  CAS  Google Scholar 

  50. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002;20:1063–8.

    Article  PubMed  CAS  Google Scholar 

  51. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808–12.

    PubMed  CAS  Google Scholar 

  52. Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17:2100–4.

    PubMed  CAS  Google Scholar 

  53. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127–34.

    PubMed  CAS  Google Scholar 

  54. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071–4.

    PubMed  CAS  Google Scholar 

  55. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol. 2003;16:574–83.

    Article  PubMed  Google Scholar 

  56. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJC. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002;86:886–92.

    Article  PubMed  CAS  Google Scholar 

  57. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer. 2003;88:115–9.

    Article  PubMed  CAS  Google Scholar 

  58. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117–22.

    Article  PubMed  Google Scholar 

  59. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247–57.

    Article  PubMed  CAS  Google Scholar 

  60. Guha M, Plescia J, Leav I, Li J, Languino LR, Altieri DC. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res. 2009;69:4954–8.

    Article  PubMed  CAS  Google Scholar 

  61. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004;279:40511–20.

    Article  PubMed  CAS  Google Scholar 

  62. Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell. 2008;32:11–20.

    Article  PubMed  Google Scholar 

  63. Pise-Masison CA, Radonovich M, Dohoney K, et al. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood. 2009;113:4016–26.

    Article  PubMed  CAS  Google Scholar 

  64. Nguyen HG, Ravid K. Tetraploidy/aneuploidy and stem cells in cancer promotion: The role of chromosome passenger proteins. J Cell Physiol. 2006;208:12–22.

    Article  PubMed  CAS  Google Scholar 

  65. Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 2007;67:339–45.

    Article  PubMed  CAS  Google Scholar 

  66. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med. 2007;13:820–7.

    Article  PubMed  CAS  Google Scholar 

  67. You L, He B, Xu Z, et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 2004;23:6170–4.

    Article  PubMed  CAS  Google Scholar 

  68. Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene. 2003;22:4266–80.

    Article  PubMed  CAS  Google Scholar 

  69. Guha M, Xia F, Raskett CM, Altieri DC. Caspase 2-mediated tumor suppression involves survivin gene silencing. Oncogene. 2010;29:1280–92.

    Article  PubMed  CAS  Google Scholar 

  70. Shinohara ET, Gonzalez A, Massion PP, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer. 2005;103:1685–92.

    Article  PubMed  CAS  Google Scholar 

  71. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617–23.

    Article  PubMed  CAS  Google Scholar 

  72. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92–5.

    Article  PubMed  CAS  Google Scholar 

  73. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005;24:2474–82.

    Article  PubMed  CAS  Google Scholar 

  74. Lu J, Tan M, Huang WC, et al. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res. 2009;15:1326–34.

    Article  PubMed  CAS  Google Scholar 

  75. Wall NR, O’Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003;63:230–5.

    PubMed  CAS  Google Scholar 

  76. Kappler M, Bache M, Bartel F, et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther. 2004;11:186–93.

    Article  PubMed  CAS  Google Scholar 

  77. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076–81.

    Article  PubMed  CAS  Google Scholar 

  78. Yamanaka K, Nakata M, Kaneko N, et al. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol. 2011;39:569–75.

    PubMed  CAS  Google Scholar 

  79. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res. 2003;9:2683–92.

    PubMed  CAS  Google Scholar 

  80. Hayashi N, Asano K, Suzuki H, et al. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate. 2005;65:10–9.

    Article  PubMed  CAS  Google Scholar 

  81. Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, et al. Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin Cancer Res. 2011;17:3716–26.

    Article  PubMed  CAS  Google Scholar 

  82. Iwasa T, Okamoto I, Takezawa K, et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer. 2010;103:36–42.

    Article  PubMed  CAS  Google Scholar 

  83. Nakahara T, Yamanaka K, Hatakeyama S, et al. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs. 2011;22:454–62.

    Article  PubMed  CAS  Google Scholar 

  84. Yamanaka K, Nakahara T, Yamauchi T, et al. Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models. Clin Cancer Res. 2011;17:5423–31.

    Article  PubMed  CAS  Google Scholar 

  85. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BK. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther. 2011;10:221–32.

    Article  PubMed  CAS  Google Scholar 

  86. •• Talbot DC, Ranson M, Davies J, et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res. 2010;16:6150-6158. Phase I, proof-of-principle study of survivin inhibition with LY2181308, showing acceptable toxicity and confirming target inhibtion.

  87. Tanioka M, Nokihara H, Yamamoto N, et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;68:505–11.

    Article  PubMed  CAS  Google Scholar 

  88. Hansen JB, Fisker N, Westergaard M, et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther. 2008;7:2736–45.

    Article  PubMed  CAS  Google Scholar 

  89. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67:8014–21.

    Article  PubMed  CAS  Google Scholar 

  90. •• Tolcher AW, Mita A, Lewis LD, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008;26:5198-5203. Phase I study of YM155 in humans showing acceptable toxicity and therapeutic efficacy in heavily pretreated patients.

  91. Satoh T, Okamoto I, Miyazaki M, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res. 2009;15:3872–80.

    Article  PubMed  CAS  Google Scholar 

  92. Giaccone G, Zatloukal P, Roubec J, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009;27:4481–6.

    Article  PubMed  CAS  Google Scholar 

  93. Chang CC, Heller JD, Kuo J, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A. 2004;101:13239–44.

    Article  PubMed  CAS  Google Scholar 

  94. Khanna N, Dalby R, Tan M, Arnold S, Stern J, Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol Oncol. 2007;107:554–62.

    Article  PubMed  CAS  Google Scholar 

  95. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001;61:869–72.

    PubMed  CAS  Google Scholar 

  96. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61:5964–8.

    PubMed  CAS  Google Scholar 

  97. Andersen MH, Soerensen RB, Becker JC. thor Straten P. HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer. J Transl Med. 2006;4:38.

    Article  PubMed  Google Scholar 

  98. Plescia J, Salz W, Xia F, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 2005;7:457–68.

    Article  PubMed  CAS  Google Scholar 

  99. Siegelin MD, Plescia J, Raskett CM, Gilbert CA, Ross AH, Altieri DC. Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. Mol Cancer Ther. 2010;9:1638–46.

    Article  PubMed  CAS  Google Scholar 

  100. Herrington WG, Talbot DC, Lahn MM, et al. Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma. Am J Kidney Dis. 2011;57:300–3.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

Dr. Church and Dr. Talbot acknowledge financial support from Cancer Research UK.

Disclosure

D. N. Church: none; D. C. Talbot: advisory board member for Lilly UK, and honoraria and an unrestricted research grant from Lilly UK.

Author information

Authors and Affiliations

  1. Oxford Cancer Centre, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, UK

    David N. Church & Denis C. Talbot

Authors
  1. David N. Church
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Denis C. Talbot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Denis C. Talbot.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Church, D.N., Talbot, D.C. Survivin in Solid Tumors: Rationale for Development of Inhibitors. Curr Oncol Rep 14, 120–128 (2012). https://doi.org/10.1007/s11912-012-0215-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-012-0215-2

Keywords

Search

Navigation